Cohort Study of the Clinical Course of Macular Diseases in Japanese

Overview

Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth.

Patients with such macular diseases are registered and and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Full Title of Study: “Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2022

Interventions

  • Drug: ranibizumab, aflibercept, pegaptanib, verteporphin

Arms, Groups and Cohorts

  • Macular diseases
    • ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡

Clinical Trial Outcome Measures

Primary Measures

  • Initial factors associated with visual prognosis in each macular disease
    • Time Frame: Five years after the registration

Secondary Measures

  • The difference in the visual prognosis depending on the treatments in each macular diseases
    • Time Frame: Five years after the registration

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who visit Department of Ophthalmology Kyoto University Hospital with macular diseases.
  • Patients who are agreed with the participation of this study.

Exclusion Criteria

  • None

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kyoto University, Graduate School of Medicine
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nagahisa Yoshimura, Professor – Kyoto University, Graduate School of Medicine
  • Overall Official(s)
    • Nagahisa Yoshimura, MD, Study Chair, Kyoto University, Graduate School of Medicine
  • Overall Contact(s)
    • Akitaka Tsujikawa, MD, +81-75-751-3260, tujikawa@kuhp.kyoto-u.ac.jp

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.